NEET PG general medicine questions

Mechanical mitral valves carry a higher thrombogenic risk than aortic prostheses because of lower flow velocities and larger surface area in the left atrium, so a higher intensity of anticoagulation is required. Current guidelines recommend a target INR of 2.5-3.5 for mechanical mitral valves, compared to 2.0-3.0 for bileaflet mechanical aortic valves without additional risk factors. The higher target balances thromboembolic risk against bleeding risk. Additional risk factors such as atrial fibrillation, prior embolism, or left ventricular dysfunction would push the target further toward the upper range or warrant combination with low-dose aspirin.

• A. This range is excessively high and increases bleeding risk without added benefit for a standard mechanical mitral valve.
• B. This range is too low and risks valve thrombosis or embolic stroke in a mechanical mitral prosthesis.
• D. This range is appropriate for a bileaflet mechanical aortic valve without risk factors, not a mitral prosthesis.

This patient's CHA2DS2-VASc score is calculated as 1 point for hypertension, 1 point for diabetes mellitus, and 1 point for age, giving a total score of 3 (age 65-74 contributes 1 point). A score of 2 or more in men indicates a significant annual stroke risk, and current guidelines recommend oral anticoagulation, preferably with a direct oral anticoagulant over warfarin in non-valvular atrial fibrillation unless contraindicated. Aspirin alone is no longer recommended for stroke prevention in atrial fibrillation given its inferior efficacy and similar bleeding risk compared to anticoagulants. Left atrial appendage occlusion is reserved for patients with contraindications to long-term anticoagulation.

• A. Withholding antithrombotic therapy is inappropriate given a CHA2DS2-VASc score of 3, which carries significant stroke risk.
• B. This device is a second-line option for patients unsuitable for long-term anticoagulation, not a first-line choice here.
• C. Aspirin monotherapy has inferior efficacy for stroke prevention in atrial fibrillation and is not recommended when anticoagulation is indicated.

Any patient with recurrence of tuberculosis after previous treatment is classified as presumptive drug-resistant TB under NTEP and must be tested with CBNAAT or line probe assay to detect rifampicin resistance before further treatment decisions. Universal drug susceptibility testing is mandatory for all previously treated cases, relapses, and treatment failures to avoid inappropriate continuation of first-line drugs in resistant disease. Early detection of resistance allows prompt initiation of an appropriate regimen and reduces transmission of drug-resistant strains. Empirical treatment without resistance testing risks further amplification of resistance.

• A. Delaying testing allows continued transmission and does not meet the criterion of universal drug susceptibility testing for previously treated cases.
• B. Restarting first-line drugs without resistance testing risks treating undetected drug-resistant disease inappropriately.
• D. Starting second-line drugs empirically without confirmed resistance is not recommended and exposes the patient to unnecessary toxicity.

Ethambutol causes dose-dependent retrobulbar optic neuritis presenting with decreased visual acuity and red-green color blindness, which is usually reversible if the drug is stopped promptly upon recognition. Isoniazid causes peripheral neuropathy by interfering with pyridoxine (vitamin B6) metabolism, so pyridoxine supplementation is given, especially in malnourished patients, pregnant women, alcoholics, and those with diabetes or HIV infection, to prevent this complication. Patients on ethambutol should have baseline and periodic visual acuity and color vision testing, and the drug should be discontinued immediately if optic neuritis develops. Rifampicin and pyrazinamide are not associated with these specific toxicities.

• A. Pyrazinamide causes hepatotoxicity and hyperuricemia, not optic neuritis, and pyridoxine is not linked to rifampicin.
• C. Isoniazid does not cause the described visual toxicity, and pyridoxine prevents isoniazid's own neuropathy, not ethambutol's effect.
• D. Rifampicin does not cause optic neuritis, and folic acid is not the standard preventive agent for isoniazid neuropathy.

This patient falls into GOLD group E (history of ≥2 moderate exacerbations or ≥1 hospitalization) with ongoing symptoms despite LABA monotherapy. GOLD 2025 recommends escalation to LABA+LAMA dual bronchodilator therapy as the next step in such patients. Inhaled corticosteroid is added only if blood eosinophils are ≥300/µL or there is a strong asthma overlap, which is not the case here (eosinophils 150/µL). Triple therapy is reserved for those who continue to exacerbate despite LABA+LAMA.

• A. Triple therapy is the next step only after escalation on LABA+LAMA fails to control exacerbations.
• B. Reducing to SABA alone would undertreat a symptomatic patient with exacerbation history.
• C. ICS add-on is favored mainly when eosinophils are ≥300/µL, not at this level.

This patient has life-threatening (near-fatal) asthma: a rising PaCO2 (52 mmHg, indicating hypoventilation and exhaustion), hypoxemia despite oxygen, acidosis, and PEFR less than 33% predicted, with no improvement despite initial therapy. These are indications for ICU transfer and consideration of mechanical ventilation, as normalizing or rising CO2 in acute severe asthma signals impending respiratory failure. Continuing standard therapy in the emergency department risks sudden deterioration or cardiorespiratory arrest. Non-invasive ventilation is not reliable in this setting of fatigue with rising CO2 and should not substitute for ICU-level monitoring and readiness for intubation.

• A. NIV has limited evidence in severe asthma and should not delay ICU transfer in a patient already showing signs of exhaustion and hypercapnia.
• B. A normalizing/rising PaCO2 with persistent hypoxemia after an hour of therapy indicates impending respiratory failure, not a situation for simple observation.
• D. Aminophylline has limited additional benefit over standard therapy and does not address the need for airway and ventilatory support in impending failure.

This patient has refractory pulmonary edema (fluid overload) unresponsive to high-dose loop diuretics, which is one of the classic indications for emergency hemodialysis, remembered by the mnemonic AEIOU: Acidosis (severe, refractory), Electrolyte imbalance (severe hyperkalemia), Ingestion (toxic alcohols, lithium, salicylates), Overload of fluid (refractory to diuretics), and Uremia (encephalopathy, pericarditis, bleeding). Diuretic-resistant pulmonary edema in a CKD patient reflects inadequate renal clearance of fluid, and further diuretic escalation will not help and may cause ototoxicity. Emergency dialysis rapidly removes excess fluid and corrects the underlying problem.

• A. Nitroglycerin reduces preload but does not address the underlying failure to excrete fluid in a patient refractory to diuretics.
• B. Delaying definitive fluid removal while repeating ineffective diuretics risks respiratory failure in a hypoxic, oliguric patient.
• C. Diuretic escalation in a patient already unresponsive to high-dose furosemide with minimal urine output is unlikely to help and may cause toxicity.

Minimal change disease is characterized by normal-appearing glomeruli on light microscopy, negative immunofluorescence, and diffuse podocyte foot process effacement on electron microscopy without any immune complex deposits or sclerotic lesions. It is the most common cause of nephrotic syndrome in children and typically responds well to corticosteroids. Focal segmental glomerulosclerosis would show segmental areas of scarring and hyalinosis on light microscopy, which are absent here. Membranous nephropathy shows subepithelial immune deposits on electron microscopy and granular IgG/C3 deposits on immunofluorescence, and membranoproliferative GN shows mesangial and endocapillary hypercellularity with basement membrane changes.

• A. FSGS requires segmental sclerotic lesions on light microscopy, which are absent in this biopsy.
• C. Membranoproliferative GN shows mesangial/endocapillary hypercellularity and basement membrane double-contour changes, not a normal-appearing glomerulus.
• D. Membranous nephropathy shows subepithelial immune deposits and positive immunofluorescence, not seen here.

The presence of dysmorphic red blood cells and red cell casts on urinalysis is diagnostic of glomerular bleeding and defines a nephritic picture, typically accompanied by hypertension, oliguria, and only mild to moderate (sub-nephrotic) proteinuria, as seen here with 1+ protein and a near-normal serum albumin. This presentation, following a sore throat by about two weeks, is classic for post-streptococcal glomerulonephritis. Nephrotic syndrome is defined by heavy proteinuria (>3.5 g/day), hypoalbuminemia, and edema from a protein-losing glomerulopathy, without the hematuria and red cell casts seen here. Minimal change disease is a cause of nephrotic, not nephritic, syndrome, and pre-renal AKI would not produce an active urinary sediment with red cell casts.

• A. Pre-renal AKI produces a bland urine sediment without red cell casts or dysmorphic RBCs.
• B. Nephrotic syndrome requires heavy proteinuria and hypoalbuminemia, neither of which is present here.
• C. Minimal change disease causes nephrotic syndrome, not a nephritic picture with red cell casts.

An eGFR below 15 mL/min/1.73m² defines CKD stage 5 (kidney failure) according to KDOQI/KDIGO classification. In the absence of an absolute indication for emergency dialysis, such as refractory hyperkalemia, pericarditis, encephalopathy, or fluid overload, initiation of renal replacement therapy in CKD stage 5 is planned electively based on symptoms, nutritional status, and trends in eGFR rather than started emergently. Current guidelines favor an individualized, symptom-based approach rather than starting dialysis purely on a GFR cutoff, and this asymptomatic patient should have vascular/peritoneal access planning initiated while continuing medical management. CKD stage 4 is defined by eGFR 15-29 mL/min/1.73m², and stage 3b by eGFR 30-44, both of which are lower than this patient's GFR category.

• A. An eGFR of 12 mL/min/1.73m² falls below the stage 4 cutoff of 15, placing him in stage 5, not stage 4.
• C. Emergency dialysis is reserved for absolute indications such as refractory hyperkalemia, pericarditis, or encephalopathy, none of which are present here.
• D. An eGFR of 12 is far below the stage 3b range of 30-44 mL/min/1.73m².

Metformin is renally cleared and accumulates in advanced chronic kidney disease, increasing the risk of lactic acidosis due to impaired lactate clearance and mitochondrial effects. It is contraindicated when eGFR falls below 30 mL/min/1.73m². Ceftriaxone is primarily hepatically eliminated and needs no renal dose adjustment. Azithromycin undergoes minimal renal excretion, and insulin dosing, while requiring monitoring, is not contraindicated in renal failure.

• A. Ceftriaxone is excreted mainly through bile and does not require dose adjustment in renal impairment.
• C. Insulin requires careful dose titration in renal failure but is not avoided; it remains the preferred glucose-lowering agent.
• D. Azithromycin is eliminated predominantly by the liver and is safe at this eGFR.

The MELD (Model for End-Stage Liver Disease) score is calculated purely from objective laboratory values: serum bilirubin, serum creatinine, and INR (sodium is included in MELD-Na), and is used to prioritize patients for liver transplantation based on 90-day mortality risk. The Child-Pugh score, in contrast, incorporates two clinical parameters (ascites and encephalopathy grade) along with bilirubin, albumin, and INR, making it partly subjective. Ranson's criteria assess severity in acute pancreatitis, not cirrhosis. APACHE II is a general ICU severity score unrelated to liver-specific prognosis.

• A. APACHE II is a general critical care severity score not specific to chronic liver disease.
• B. Ranson's criteria are used to assess severity and prognosis in acute pancreatitis, not cirrhosis.
• C. Child-Pugh score includes clinical assessment of ascites and encephalopathy in addition to laboratory values, unlike the purely objective MELD score.

Persistent HBsAg beyond six months with IgG (not IgM) anti-HBc, anti-HBe positivity, HBeAg negativity, and low HBV DNA (typically under 2000 IU/mL) indicates the inactive HBsAg carrier state, a chronic infection with low replicative activity and minimal liver inflammation. Acute hepatitis B shows IgM anti-HBc positivity, which is absent here. Resolved infection shows HBsAg negative with anti-HBs and anti-HBc positive. The window period shows HBsAg negative, anti-HBs negative, with only IgM anti-HBc positive bridging the gap.

• A. Acute infection requires IgM anti-HBc positivity, which is negative in this patient.
• B. The window period shows HBsAg negativity with isolated IgM anti-HBc positivity, not the chronic pattern described.
• D. Resolved infection requires HBsAg to be negative with anti-HBs positive, not the HBsAg-positive pattern seen here.

In suspected variceal bleeding, vasoactive drugs such as octreotide should be started immediately to reduce splanchnic blood flow and portal pressure, combined with upper GI endoscopy performed within 12 hours for diagnosis and endoscopic variceal band ligation, the preferred endoscopic modality over sclerotherapy due to lower rebleeding and complication rates. Proton pump inhibitors are used for peptic ulcer bleeding, not as first-line for variceal hemorrhage. Propranolol is used for primary or secondary prophylaxis, not acute bleeding, and endoscopy must not be delayed to 72 hours in an actively bleeding patient. Balloon tamponade is a temporizing measure for refractory bleeding, not definitive therapy, and vitamin K has no role in acute variceal hemorrhage.

• A. PPI infusion and sclerotherapy are used for non-variceal bleeding; band ligation is preferred over sclerotherapy for varices.
• B. Propranolol is for prophylaxis, not acute bleeding, and endoscopy should not be delayed in an actively bleeding unstable patient.
• D. Balloon tamponade is only a temporizing bridge measure, not definitive management, and vitamin K is not indicated here.

Lactulose is a non-absorbable disaccharide that reaches the colon unchanged, where bacterial fermentation produces lactic and acetic acid, lowering colonic pH. This acidic environment converts absorbable ammonia (NH3) into non-absorbable ammonium (NH4+), which is trapped in the gut lumen and eliminated in stool, thereby lowering serum ammonia. Hypokalemia from diuretic use is a recognized precipitant of hepatic encephalopathy because it promotes renal ammonia generation. Lactulose has no direct chelating action in blood, does not inhibit urea cycle enzymes, and its laxative action in the gut, not renal diuresis, is responsible for ammonia elimination.

• A. Lactulose does not inhibit hepatic enzymes; its effect is purely at the level of the colon.
• B. Lactulose acts in the gut lumen, not the bloodstream, and has no chelating property.
• D. Lactulose works through its colonic osmotic laxative effect, not through renal diuresis.

Standard first-line triple therapy for Helicobacter pylori eradication consists of a proton pump inhibitor combined with amoxicillin and clarithromycin, given for 14 days to maximize eradication rates, provided local clarithromycin resistance is low. The rapid urease test exploits the bacterium's urease enzyme, which splits urea to ammonia and carbon dioxide, causing a color change in the test medium. Doxycycline-metronidazole is not a standard first-line regimen for H. pylori. Sucralfate and PPI alone lack antibacterial activity against H. pylori. Ciprofloxacin-azithromycin is not a guideline-recommended combination for eradication.

• A. Doxycycline and metronidazole without a PPI and additional antibiotic is not a standard first-line eradication regimen.
• C. Sucralfate with PPI has no antimicrobial activity against H. pylori and will not achieve eradication.
• D. Ciprofloxacin and azithromycin is not a recommended first-line combination for H. pylori eradication.

This patient has classic diabetic ketoacidosis: hyperglycemia, high anion gap metabolic acidosis, and positive ketones, distinguishing it from HHS which typically shows glucose over 600 mg/dL, minimal ketosis, and near-normal pH. Management begins with isotonic saline (0.9% NaCl) to restore intravascular volume, followed by or concurrent with a continuous intravenous regular insulin infusion to suppress ketogenesis and lower glucose. Potassium is currently elevated (5.8 mEq/L) due to acidosis-driven extracellular shift despite total body depletion, so insulin and fluids are given first; potassium replacement is added once levels fall below 5.0-5.3 mEq/L. Bicarbonate is reserved only for severe acidosis with pH below 6.9 and is not a first-line measure in standard DKA protocols.

• A. Routine bicarbonate use is not recommended in DKA unless pH is below 6.9, and correcting acidosis without insulin does not address the underlying ketogenesis.
• C. Her potassium is already elevated at 5.8 mEq/L; giving more potassium before insulin risks dangerous hyperkalemia.
• D. Subcutaneous insulin has unreliable absorption in DKA with poor peripheral perfusion, and oral rehydration is inappropriate in a drowsy, vomiting patient.

Empagliflozin belongs to the SGLT2 inhibitor class, which blocks the sodium-glucose cotransporter 2 in the proximal renal tubule, reducing glucose reabsorption and causing glucosuria. This glucosuria produces osmotic diuresis, explaining the increased urinary frequency, and creates a favorable environment for genital mycotic infections such as vulvovaginal candidiasis, a well-recognized class adverse effect. SGLT2 inhibitors also have proven cardiovascular and renal benefits, including reduction in heart failure hospitalizations, making this class particularly suitable for her comorbidity profile. DPP-4 inhibitors, thiazolidinediones, and sulfonylureas do not cause glucosuria and are not associated with this adverse effect pattern.

• A. Sulfonylureas like glimepiride stimulate insulin secretion and are more associated with hypoglycemia than genital infections.
• B. DPP-4 inhibitors like sitagliptin increase incretin levels and do not cause glucosuria or genital infections.
• D. Pioglitazone acts on PPAR-gamma receptors and is associated with weight gain and fluid retention, not glucosuria.

Metformin is renally cleared, and its accumulation in significant renal impairment increases the risk of lactic acidosis because the drug inhibits hepatic gluconeogenesis via mitochondrial effects that also impair lactate clearance. Current guidelines contraindicate metformin when eGFR falls below 30 mL/min/1.73m², making discontinuation and switching to an alternative agent such as insulin or a DPP-4 inhibitor the correct approach in this patient with eGFR of 22 mL/min/1.73m². Continuing metformin, even at reduced dose, in this range of renal function carries unacceptable risk of lactic acidosis, which is further compounded by the risk of contrast-induced nephropathy from the planned CT scan. Bicarbonate supplementation does not mitigate the fundamental risk of drug accumulation and is not a recognized strategy for continuing metformin in severe renal impairment.

• A. Bicarbonate does not address the underlying accumulation risk and is not a standard mitigation strategy.
• B. Continuing at this GFR level carries a significant risk of lactic acidosis, especially given the planned contrast study.
• C. Metformin is contraindicated below eGFR 30 mL/min/1.73m² regardless of dose reduction.

This patient has Graves disease, confirmed by suppressed TSH, elevated free T4, and positive TSH receptor antibodies, presenting in the first trimester of pregnancy. Propylthiouracil is preferred over carbimazole (or methimazole) specifically during the first trimester because carbimazole carries a higher risk of teratogenic effects, including aplasia cutis and choanal or esophageal atresia, which occur during the critical period of organogenesis. After the first trimester, guidelines recommend switching to carbimazole or methimazole because propylthiouracil carries a small but serious risk of hepatotoxicity with longer-term use. Radioactive iodine is absolutely contraindicated in pregnancy due to fetal thyroid ablation risk, and propranolol alone only controls adrenergic symptoms without treating the underlying hormone excess.

• A. Radioactive iodine is absolutely contraindicated in pregnancy due to the risk of fetal thyroid ablation.
• B. Carbimazole is avoided in the first trimester due to teratogenic risk and is preferred only after the first trimester.
• D. Propranolol only controls symptoms like tachycardia and does not treat the underlying thyrotoxicosis.

This patient is in adrenal (Addisonian) crisis, precipitated by the physiological stress of acute gastroenteritis in a patient with primary adrenal insufficiency who could not absorb or adequately increase her oral steroid intake due to vomiting and diarrhea. Immediate management requires an intravenous hydrocortisone bolus (100 mg) to rapidly replace glucocorticoid deficiency, combined with aggressive isotonic saline infusion to correct hypotension and hypoglycemia. Oral therapy is inappropriate in a vomiting, hemodynamically unstable patient because absorption cannot be relied upon. While dexamethasone has been used historically, hydrocortisone is preferred because it has combined glucocorticoid and mineralocorticoid activity, whereas intramuscular depot steroids act too slowly for this emergency and fluid resuscitation cannot be delayed.

• A. Oral agents are unreliable in a vomiting, hemodynamically unstable patient and do not provide rapid correction.
• C. Fluid resuscitation is essential and cannot be omitted in a hypotensive crisis state.
• D. Intramuscular depot steroids have delayed onset and are unsuitable for an acute life-threatening crisis.

The pattern of elevated ACTH with suppression on high-dose but not low-dose dexamethasone is classic for Cushing disease caused by an ACTH-secreting pituitary adenoma. Pituitary corticotroph adenomas retain partial sensitivity to glucocorticoid negative feedback, so high-dose dexamethasone suppresses ACTH and cortisol by more than 50%, whereas low-dose dexamethasone is insufficient to overcome the relatively higher feedback threshold. Adrenal adenomas are ACTH-independent and would show a suppressed, not elevated, ACTH level. Ectopic ACTH sources such as bronchial carcinoids are typically autonomous and resistant to suppression even at high dexamethasone doses, which is the key feature distinguishing them from pituitary disease.

• A. Exogenous glucocorticoid use suppresses endogenous ACTH and would not produce an elevated ACTH level.
• B. Ectopic ACTH sources typically fail to suppress even with high-dose dexamethasone, unlike the pattern seen here.
• C. Adrenal adenomas cause ACTH-independent Cushing syndrome with suppressed, not elevated, ACTH levels.

Current NACO guidelines, aligned with WHO recommendations, mandate a test-and-treat strategy in which antiretroviral therapy is initiated in every person diagnosed with HIV regardless of CD4 count or clinical stage, since earlier treatment reduces morbidity, mortality, and onward transmission. The first-line regimen recommended is a fixed-dose combination of tenofovir disoproxil fumarate, lamivudine, and dolutegravir (TLD), given once daily, reflecting dolutegravir's superior efficacy, high genetic barrier to resistance, and good tolerability compared to older regimens. Deferring treatment until the CD4 count drops or until an opportunistic infection develops contradicts the test-and-treat principle and exposes the patient to avoidable immune decline and transmission risk. Zidovudine-lamivudine-nevirapine was an older first-line regimen but has been phased out in favor of dolutegravir-based therapy due to better tolerability and efficacy.

• A. Waiting for an opportunistic infection contradicts the test-and-treat approach and increases morbidity and transmission risk.
• B. This older nevirapine-based regimen has been replaced by dolutegravir-based first-line therapy due to better efficacy and tolerability.
• C. Current guidelines do not use a CD4 threshold to defer treatment; therapy is initiated immediately upon diagnosis.

NACO and WHO guidelines recommend cotrimoxazole preventive therapy (CPT) in all HIV-infected adults with a CD4 count below 200 cells/mm³, or WHO clinical stage 3 or 4 disease regardless of CD4 count, mainly to prevent Pneumocystis jirovecii pneumonia and toxoplasmosis. Cotrimoxazole also reduces bacterial infections and malaria incidence in endemic areas. It is typically given as trimethoprim-sulfamethoxazole 960 mg once daily and continued until CD4 count rises above 200 cells/mm³ for at least 6 months on ART. This patient's CD4 count of 180 cells/mm³ meets the threshold for initiation.

• B. Azithromycin prophylaxis for disseminated MAC is reserved for CD4 counts below 50 cells/mm³.
• C. Isoniazid prophylaxis targets tuberculosis, not the broader opportunistic infection risk defined by this CD4 threshold.
• D. Fluconazole prophylaxis is not routinely recommended due to risk of resistance and is reserved for recurrent candidiasis or cryptococcal disease.

NVBDCP recommends artemisinin-based combination therapy (ACT) for uncomplicated P. falciparum malaria, specifically artesunate (days 1-3) plus sulfadoxine-pyrimethamine (day 1) for 3 days, combined with a single dose of primaquine (0.75 mg/kg) on day 1 to reduce gametocyte transmission. This differs from P. vivax malaria, which is treated with chloroquine for 3 days plus primaquine 0.25 mg/kg daily for 14 days to achieve radical cure by eliminating hepatic hypnozoites. Chloroquine monotherapy is not used for P. falciparum due to widespread resistance in India. Quinine plus doxycycline is reserved for areas with ACT failure or as an alternative regimen, not first-line.

• A. Chloroquine is not effective first-line therapy for P. falciparum due to resistance, and single-dose primaquine without the 14-day course does not apply to vivax radical cure either.
• B. Quinine plus doxycycline is a second-line or alternative regimen, not the first-line NVBDCP recommendation.
• D. This 14-day primaquine regimen with chloroquine is the treatment for P. vivax, not P. falciparum, and chloroquine resistance is widespread in falciparum malaria.

This patient has dengue with warning signs, including abdominal pain, vomiting with blood streaks, and a rising hematocrit with falling platelet count, which per WHO/NVBDCP classification mandates hospital admission for close monitoring even in the absence of hypotension or frank shock. Warning signs also include persistent vomiting, mucosal bleeding, lethargy, liver enlargement greater than 2 cm, and clinical fluid accumulation. Patients with warning signs require inpatient monitoring of vitals, hematocrit, and platelet counts to detect early progression to severe dengue (plasma leakage, severe bleeding, or organ impairment). Outpatient management is reserved for dengue without warning signs with stable hemodynamics and adequate oral intake.

• B. Prophylactic platelet transfusion is not indicated based on platelet count alone in the absence of significant bleeding, and this cannot be managed as outpatient day care given warning signs.
• C. Discharge is inappropriate because the presence of warning signs mandates hospitalization for monitoring of possible progression to severe dengue.
• D. There is no indication of bacterial superinfection; the clinical picture is consistent with dengue with warning signs requiring supportive care, not antibiotics.

Blood culture is the gold standard investigation for enteric fever and has the highest sensitivity during the first week of illness, when bacteremia is at its peak, typically detecting Salmonella Typhi or Paratyphi in 60-80% of cases if collected before antibiotics are started. The Widal test lacks sensitivity and specificity in the first week since antibody titers (agglutinins) usually rise only after the second week, and cross-reactivity with other infections limits its reliability. Stool culture becomes more useful later in the illness (second to third week) as the organism is shed in feces, but it is not the best initial test in the first week. Rapid serological tests like Typhidot have variable sensitivity and specificity and are not preferred over blood culture during early bacteremic illness.

• B. Stool culture has low yield in the first week of illness and becomes more positive in the second to third week.
• C. Widal test has poor sensitivity in the first week since antibody titers have not yet risen to diagnostic levels.
• D. Rapid IgM-based tests have variable sensitivity and specificity and are inferior to blood culture as the confirmatory test.

Given the widespread emergence of fluoroquinolone-resistant and nalidixic acid-resistant Salmonella Typhi strains in India, third-generation cephalosporins such as intravenous ceftriaxone (2 g once daily for 10-14 days) are now the preferred empirical treatment for enteric fever, especially in hospitalized or moderately-to-severely ill patients. Ciprofloxacin, once first-line, is no longer reliable empirically due to resistance and should only be used if susceptibility is confirmed. Chloramphenicol and amoxicillin are older agents with variable resistance patterns and are reserved for susceptible isolates or used as step-down oral therapy (azithromycin or cefixime) in milder cases. Azithromycin is an acceptable oral alternative for uncomplicated cases, but among the options given, ceftriaxone is the standard empirical choice.

• A. Chloramphenicol resistance is common and it is reserved for confirmed susceptible strains, not empirical use.
• C. Amoxicillin resistance is frequent and it is not the preferred empirical agent in resistant settings.
• D. Fluoroquinolone resistance is now widespread, making ciprofloxacin unreliable as empirical therapy.

This patient has severe leptospirosis with Weil's syndrome (jaundice, renal impairment), classically acquired through contact with water contaminated by animal urine harboring Leptospira. For severe disease requiring hospitalization, intravenous penicillin G (1.5 million units every 6 hours) is the first-line antibiotic, as it has long been the standard therapy demonstrated to reduce mortality and duration of illness. Intravenous ceftriaxone is an equally effective alternative in penicillin-allergic patients. Doxycycline is used for mild, early, outpatient-treated leptospirosis but is not preferred in severe disease requiring parenteral therapy, especially with renal and hepatic involvement. Supportive care, including dialysis if needed for renal failure, is also essential in severe cases.

• B. Doxycycline is used for mild outpatient leptospirosis, not for severe disease with renal and hepatic failure requiring parenteral therapy.
• C. Ciprofloxacin is not a standard first-line agent for leptospirosis.
• D. Azithromycin is not the preferred agent for severe leptospirosis with organ involvement.

This patient meets several SLICC/ACR criteria for systemic lupus erythematosus: malar rash, oral ulcers, arthritis, and renal involvement (proteinuria). While ANA is the most sensitive screening test and is positive in nearly all SLE patients, it is not specific, as it is also seen in other autoimmune and infectious conditions. Anti-double stranded DNA antibody is highly specific for SLE, correlates with disease activity (especially lupus nephritis), and is one of the immunologic criteria used in classification. Anti-histone antibodies are characteristic of drug-induced lupus, not spontaneous SLE. Rheumatoid factor is associated with rheumatoid arthritis and is nonspecific.

• A. ANA is highly sensitive but not specific for SLE; it is positive in many other autoimmune diseases.
• B. Anti-histone antibody points to drug-induced lupus rather than idiopathic SLE.
• C. Rheumatoid factor is nonspecific and more characteristic of rheumatoid arthritis.

Rheumatoid factor has good sensitivity for rheumatoid arthritis but poor specificity, as it is also found in Sjögren syndrome, SLE, chronic infections, and even in healthy elderly individuals. Anti-citrullinated protein antibody (anti-CCP) has comparable sensitivity to RF but much higher specificity (around 95%) for rheumatoid arthritis, and its presence often predicts more erosive joint disease. Anti-CCP can also appear years before clinical onset of RA, making it useful for early diagnosis. ANA is nonspecific and seen in multiple connective tissue diseases, while Anti-Ro/SSA is associated with Sjögren syndrome and HLA-B27 with seronegative spondyloarthropathies.

• A. Anti-Ro/SSA antibody is characteristic of Sjögren syndrome, not rheumatoid arthritis.
• B. ANA is a nonspecific marker seen across multiple autoimmune connective tissue diseases.
• C. HLA-B27 is associated with seronegative spondyloarthropathies, not rheumatoid arthritis.

Anemia of chronic disease, seen commonly in chronic inflammatory conditions like rheumatoid arthritis, results from increased hepcidin levels that trap iron within macrophages and reduce its availability for erythropoiesis. This produces a characteristic pattern of low serum iron, low TIBC (due to reduced transferrin synthesis), and normal or raised ferritin (an acute phase reactant reflecting iron stores and inflammation), unlike iron deficiency anemia where TIBC is raised and ferritin is low. True iron deficiency anemia would show low ferritin along with low iron and high TIBC. Thalassemia trait typically shows normal or raised iron studies with a disproportionately low MCV for the degree of anemia. Sideroblastic anemia shows high serum iron and ferritin with ringed sideroblasts on marrow examination.

• B. Sideroblastic anemia shows high serum iron and ferritin, not low iron with low TIBC.
• C. Thalassemia trait typically shows normal iron studies with disproportionately microcytic cells.
• D. Iron deficiency anemia shows raised TIBC and low ferritin, the opposite of this pattern.

The clinical picture of macrocytic anemia with neurological symptoms (peripheral neuropathy) and glossitis in a strict vegetarian strongly suggests vitamin B12 deficiency causing megaloblastic anemia. The peripheral smear in megaloblastic anemia classically shows hypersegmented neutrophils (more than 5 nuclear lobes) and macro-ovalocytes due to impaired DNA synthesis affecting rapidly dividing cells. Target cells and pencil cells are typically seen in thalassemia and severe iron deficiency, respectively. Microcytic hypochromic cells with anisopoikilocytosis are characteristic of iron deficiency anemia, which is a microcytic process, inconsistent with the raised MCV here. Basophilic stippling is associated with lead poisoning or thalassemia, not megaloblastic anemia.

• B. Basophilic stippling is typical of lead poisoning or thalassemia, not megaloblastic anemia.
• C. Target cells and pencil cells are seen in thalassemia and iron deficiency, both microcytic conditions.
• D. This pattern is seen in iron deficiency anemia, a microcytic process, not consistent with the elevated MCV here.

This patient's presentation of fever, neurological symptoms, thrombocytopenia, microangiopathic hemolytic anemia (schistocytes), and renal impairment with normal coagulation studies is classic for thrombotic thrombocytopenic purpura, caused by ADAMTS13 deficiency leading to unregulated platelet-rich microthrombi formation. Plasma exchange is the definitive emergency treatment, as it removes autoantibodies against ADAMTS13 and replenishes the deficient enzyme, and must be started urgently because untreated TTP has a very high mortality. Platelet transfusion is avoided in TTP as it can worsen microthrombosis and precipitate further organ damage. Intravenous immunoglobulin and corticosteroids alone are used in immune thrombocytopenic purpura, which lacks the hemolysis, fever, and organ dysfunction seen here.

• A. Corticosteroids alone are insufficient in TTP; plasma exchange is required urgently for this life-threatening condition.
• B. Platelet transfusion can worsen microthrombus formation in TTP and is generally avoided.
• D. Intravenous immunoglobulin is used in ITP, which does not present with hemolysis and organ dysfunction.

This patient has an acute ischemic stroke presenting within 4.5 hours of symptom onset, with no contraindications such as hemorrhage on CT, recent surgery, or anticoagulant use, making him eligible for intravenous thrombolysis with alteplase (recombinant tissue plasminogen activator). Thrombolysis within this window significantly improves functional outcomes by restoring perfusion before irreversible infarction occurs, and blood pressure should be controlled to below 185/110 mmHg prior to administration. Dual antiplatelet therapy is used for minor strokes or TIAs but is not the acute reperfusion treatment of choice here given eligibility for thrombolysis. Heparin is not used in acute ischemic stroke due to bleeding risk without proven benefit. Waiting for a repeat CT would unacceptably delay time-sensitive treatment and worsen the outcome.

• A. Dual antiplatelet therapy is used for minor stroke or TIA, not as first-line reperfusion therapy when thrombolysis is possible.
• B. Heparin has no proven benefit in acute ischemic stroke and increases bleeding risk.
• D. Delaying treatment to repeat imaging wastes critical time within the thrombolysis window and worsens outcomes.

The upper facial muscles (frontalis, orbicularis oculi) receive bilateral cortical innervation, so an upper motor neuron lesion spares them, and the patient can still wrinkle the forehead. A lower motor neuron lesion (as in Bell's palsy, affecting the facial nerve nucleus or nerve itself) causes paralysis of the entire half of the face, including the forehead, because it has no alternate bilateral input. Therefore, loss of forehead wrinkling localizes the lesion to the facial nerve or its nucleus, distal to the point where bilateral cortical fibers converge. This is the classic bedside distinguishing sign taught for facial palsy localization.

• A. Inability, not preserved ability, to close the eye is seen in LMN palsy; preserved closure would suggest UMN sparing.
• C. This pattern (lower face weaker than upper face) is characteristic of UMN lesions, not LMN lesions.
• D. Combined limb and facial weakness suggests a central (UMN) lesion such as stroke, not isolated LMN facial palsy.

This patient has Guillain-Barré syndrome with the classic CSF finding of albuminocytologic dissociation: markedly raised protein with a normal or near-normal cell count. The major life-threatening complication of GBS is respiratory muscle weakness leading to ventilatory failure. Forced vital capacity is the key bedside parameter to monitor serially; a decline below approximately 15-20 mL/kg (or below 1 liter in an adult) signals impending respiratory failure and the need for elective intubation and mechanical ventilation. Repeating CSF protein or nerve conduction studies does not help predict acute respiratory decline.

• A. Creatine kinase reflects muscle breakdown and is not used to predict respiratory failure in GBS.
• B. Nerve conduction studies help confirm the diagnosis but are not a practical tool for serial respiratory monitoring.
• D. CSF protein is useful diagnostically but does not change rapidly enough to guide minute-to-minute respiratory decisions.

Acute bacterial meningitis classically produces a CSF profile of markedly elevated neutrophil-predominant pleocytosis (often >1000 cells/mm³), high protein, and low glucose with a CSF-to-blood glucose ratio below 0.4, reflecting bacterial consumption of glucose and an intense neutrophilic inflammatory response. Viral meningitis typically shows lymphocytic pleocytosis with normal glucose. Tuberculous and fungal meningitis also show low glucose but with a lymphocytic or mixed pleocytosis and a more indolent, subacute course rather than the florid neutrophilic response seen here. The combination of very high cell count, neutrophil predominance, and markedly low glucose points to a bacterial etiology.

• A. Tuberculous meningitis typically shows lymphocytic pleocytosis with a more gradual onset, not an acute neutrophilic response.
• B. Fungal meningitis usually shows lymphocytic or mixed pleocytosis, typically in immunocompromised patients with a subacute course.
• C. Viral meningitis shows lymphocytic predominance and normal CSF glucose, not neutrophilic pleocytosis with low glucose.

Organophosphates inhibit acetylcholinesterase, causing accumulation of acetylcholine at muscarinic and nicotinic receptors, producing the classic cholinergic toxidrome of salivation, lacrimation, bronchorrhea, bradycardia, and miosis. Atropine antagonizes the muscarinic effects, and the clinical endpoint of adequate atropinization is drying of secretions with a clear chest, tachycardia (heart rate above 80-90/min), and mild mydriasis, not a fixed heart rate or pupil size target. Fasciculations and muscle weakness are nicotinic effects and do not respond to atropine; they require pralidoxime, which reactivates acetylcholinesterase. Resolution of bronchorrhea and clear lung fields remain the key bedside markers for titrating atropine dose.

• B. Adequate atropinization is associated with tachycardia, not a heart rate below 60/min.
• C. Adequate atropinization causes mild pupillary dilation (mydriasis), not return to miosis.
• D. Fasciculations are a nicotinic effect unresponsive to atropine; they improve with pralidoxime, which reactivates acetylcholinesterase.

This patient's bleeding manifestations without neurological signs point to hemotoxic envenomation, typically from Russell's viper or saw-scaled viper in India. The 20-minute whole blood clotting test (20WBCT) is the bedside test of choice: venous blood is placed in a clean, dry glass tube and left undisturbed for 20 minutes, and failure of the blood to clot indicates venom-induced consumption coagulopathy from procoagulant toxins depleting fibrinogen and clotting factors. A normal firm clot within minutes indicates intact coagulation and no significant coagulopathy. The 20WBCT is simple, inexpensive, and widely used in India to decide on antivenom administration in suspected viper bites.

• A. Clot retraction with serum separation is a feature of normal clotting, not of coagulopathy.
• C. A friable or fragile clot is not the defined criterion; the standard positive 20WBCT result is complete failure of clot formation.
• D. A firm clot forming quickly indicates normal coagulation, not venom-induced coagulopathy.

Anaphylaxis is a life-threatening systemic hypersensitivity reaction, and intramuscular adrenaline is the first-line treatment of choice, given promptly into the anterolateral thigh at a dose of 0.5 mg of 1:1000 solution in adults, repeated every 5-15 minutes if needed. Adrenaline acts on alpha-1 receptors to reverse vasodilation and hypotension, and on beta-2 receptors to relieve bronchospasm and reduce further mediator release from mast cells. Corticosteroids and antihistamines are useful adjuncts but have delayed onset of action and do not reverse the acute airway or circulatory compromise. Nebulized salbutamol helps bronchospasm but does not address hypotension, the more immediately life-threatening feature here.

• A. Nebulized salbutamol treats bronchospasm alone and does not address the hypotension central to this presentation.
• C. Antihistamines help cutaneous symptoms but act slowly and do not reverse hypotension or airway compromise.
• D. Hydrocortisone has a delayed onset of action and is an adjunct, not the first-line treatment for acute anaphylaxis.

ST elevation in leads II, III and aVF localizes infarction to the inferior wall of the left ventricle, which is supplied by the right coronary artery (or a dominant left circumflex in a minority of patients, but RCA is the most common and expected answer). Reciprocal depression in I and aVL supports this territory. Inferior STEMI is often associated with bradyarrhythmias and right ventricular involvement, requiring caution with nitrates. Right-sided leads (V4R) should be checked to rule out RV infarction.

• A. LAD occlusion produces anterior STEMI with changes in V1-V4, not II, III, aVF.
• B. Left main occlusion causes extensive anterior and lateral changes with widespread ST depression, not an isolated inferior pattern.
• D. Circumflex occlusion typically causes lateral STEMI (I, aVL, V5-V6), a less common cause of inferior pattern.

Killip class II is defined by the presence of mild to moderate heart failure, clinically evidenced by basal crepitations (less than 50% of lung fields), an S3 gallop, or elevated jugular venous pressure, without pulmonary edema or cardiogenic shock. This patient has bibasal crepitations without frank pulmonary edema or shock, fitting class II. The Killip classification predicts short-term mortality after acute MI and guides triage and monitoring intensity.

• A. Killip class IV denotes cardiogenic shock with hypotension and hypoperfusion, absent here as blood pressure is maintained.
• B. Killip class III requires overt pulmonary edema with crepitations throughout both lung fields.
• D. Killip class I denotes no clinical signs of heart failure, which does not match this patient's crepitations.

When primary PCI cannot be performed within 120 minutes of first medical contact, thrombolytic therapy should be given promptly, ideally within 30 minutes of hospital arrival (door-to-needle time), to restore coronary flow and limit myocardial damage. In this scenario, transfer would take over 3 hours, exceeding the 120-minute PCI window, making thrombolysis the guideline-recommended strategy. Door-to-balloon time target for primary PCI is 90 minutes when PCI is readily available, but this is not feasible here.

• A. Delaying definitive reperfusion for a week in an evolving STEMI risks extensive myocardial necrosis and complications.
• B. Antiplatelet therapy alone without reperfusion therapy is inadequate for STEMI management.
• D. Transfer taking over 3 hours far exceeds the 120-minute window within which PCI is preferred over thrombolysis.

Carditis (manifesting here as a new pansystolic murmur of mitral regurgitation) is one of the five major Jones criteria for acute rheumatic fever, along with polyarthritis, chorea, erythema marginatum, and subcutaneous nodules. Elevated ESR, fever and arthralgia are minor criteria. Diagnosis requires evidence of preceding streptococcal infection plus either two major criteria or one major and two minor criteria. This child has polyarthritis and carditis as two major criteria, supporting the diagnosis.

• B. Elevated ESR is a minor criterion, not a major one.
• C. Fever is classified as a minor criterion in the Jones criteria.
• D. Arthralgia (joint pain without swelling) is a minor criterion; polyarthritis itself is the major criterion.

A loud first heart sound, an opening snap, and a low-pitched mid-diastolic rumbling murmur accentuated in the left lateral position are classic for mitral stenosis, caused by rheumatic thickening and fusion of the mitral valve leaflets restricting diastolic flow from left atrium to left ventricle. The opening snap results from sudden halting of the doming anterior mitral leaflet. Mitral regurgitation instead produces a pansystolic murmur radiating to the axilla, not a diastolic murmur with an opening snap.

• B. Aortic regurgitation produces an early diastolic decrescendo murmur at the left sternal border, not a mid-diastolic rumble with opening snap at the apex.
• C. Tricuspid stenosis gives a diastolic murmur at the lower left sternal border that increases with inspiration, not at the apex.
• D. Mitral regurgitation causes a pansystolic murmur at the apex radiating to the axilla, not a diastolic murmur with opening snap.

The modified Duke criteria classify a case as definite infective endocarditis when two major criteria are met: typical microorganisms (such as Streptococcus viridans) from separate blood cultures, and echocardiographic evidence of a vegetation. This patient fulfills both major criteria independently, satisfying the requirement of two major criteria for definite endocarditis. Splinter hemorrhages are a minor criterion (vascular phenomenon) but are not needed once two major criteria are present.

• A. Possible endocarditis applies when criteria fall short of definite, such as one major plus one minor criterion, not when two major criteria are fully met.
• B. The diagnosis can already be confirmed with existing data; repeat cultures are not required when two major criteria are satisfied.
• D. Rejected endocarditis applies when an alternative diagnosis is firmly established or criteria resolve with short antibiotic course; this does not apply here.

ACE inhibitors such as enalapril reduce afterload and inhibit the renin-angiotensin-aldosterone system, and have been shown in landmark trials (such as CONSENSUS and SOLVD) to significantly reduce mortality in heart failure with reduced ejection fraction. Diuretics like furosemide and metolazone provide symptomatic relief of congestion by promoting natriuresis but do not alter the natural history or mortality of heart failure. Mineralocorticoid antagonists do reduce mortality, but only when added to background ACE inhibitor or ARB therapy as part of guideline-directed regimens, not as monotherapy replacing it.

• A. Increasing furosemide dose improves symptom control but has no proven mortality benefit in heart failure.
• B. Spironolactone reduces mortality only when used alongside ACE inhibitor/ARB therapy, not as a substitute monotherapy.
• D. Metolazone is a thiazide-like diuretic used for diuretic resistance and provides only symptomatic benefit.